[¹⁸F]AmBF3-TATE is a somatostatin agonist that selectively binds to somatostatin receptor subtype 2 (SSTR2). For clinical translation, pharmacokinetics, radiation dosimetry, and acute toxicity of [¹⁸F]AmBF3-TATE were assessed with good laboratory practice (GLP) standards.

Neuroendocrine tumors (NET) are low-incidence cancers that originate from the neuroendocrine system [1].
NETs can arise from many anatomical sites with approximately 70% of cases derived from gastrointestinal origin [1]. Because NETs tend to be indolent and slow growing, patients can be asymptomatic for years for non-secreting tumors. Consequently, a significant number of patients present with high tumor burden or metastatic disease at diagnosis [1]. Radiolabeled somatostatin analogs have been used as nuclear imaging agents as NETs commonly overexpress somatostatin receptor subtype 2 (SSTR2). Clinically used SSTR2-targeting positron emission tomography (PET) agents include, but are not limited to, [⁶⁸Ga]Ga-DOTA-TATE, [⁶⁸Ga]Ga-DOTATOC,
and [⁶⁸Ga]Ga-NODAGA-JR11 [2, 3]. These somatostatin analogs can be radiolabeled with beta-emitting radionuclides (e.g., lutetium-177) for peptide receptor radionuclide therapy.

If you wish to read the whole publication, please contact us

Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE

Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [¹⁸F]AmBF3-TATE